These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 25000502)

  • 21. The level of HBV DNA at month 12 is an important predictor of virological breakthrough during adefovir monotherapy in chronic hepatitis B patients with lamivudine resistance.
    Kim MC; Jung SW; Shin JW; Park NH
    Dig Dis Sci; 2011 Apr; 56(4):1215-21. PubMed ID: 21221793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy.
    Wang Y; Liu S; Chen Y; Zheng S; Zhou L; Lu F; Duan Z
    Int J Med Sci; 2015; 12(5):416-22. PubMed ID: 26005376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nucleos(t)ide analogues altered quasispecies composition of hepatitis B virus (HBV)-resistant mutations in serum HBV DNA and serum HBV RNA.
    Liao H; Zhang H; Shao J; Li X; Zheng WV; Li L; Yu G; Si L; Zhou T; Yao Z; Dai J; Xu D; Cheng G; Qu J; Liu Y; Chen J; Lu F
    J Med Virol; 2023 Mar; 95(3):e28612. PubMed ID: 36840474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients.
    Stalke P; Rybicka M; Wróblewska A; Dreczewski M; Stracewska E; Smiatacz T; Bielawski KP
    Med Sci Monit; 2014 Feb; 20():321-8. PubMed ID: 24569300
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.
    Seto WK; Lai CL; Fung J; Wong DK; Yuen JC; Hung IF; Yuen MF
    J Hepatol; 2011 Sep; 55(3):522-528. PubMed ID: 21147187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B.
    Mirandola S; Campagnolo D; Bortoletto G; Franceschini L; Marcolongo M; Alberti A
    J Viral Hepat; 2011 Jul; 18(7):e212-6. PubMed ID: 21692935
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A European multicientre study on the comparison of HBV viral loads between VERIS HBV assay and Roche COBAS
    Braun P; Delgado R; Drago M; Fanti D; Fleury H; Izopet J; Lombardi A; Marcos M; Sauné K; O'Shea S; Pérez-Rivilla A; Ramble J; Trimoulet P; Vila J; Whittaker D; Artus A; Rhodes D
    J Clin Virol; 2017 Oct; 95():76-83. PubMed ID: 28892764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Performance Evaluation of the Beckman Coulter DxN VERIS Hepatitis B Virus (HBV) Assay in Comparison With the Abbott RealTime HBV Assay.
    Park J; Cho H; Choi SJ; Lee GD; Sin SH; Ryu JH; Park HS; Lee H; Kim Y; Oh EJ
    Ann Lab Med; 2019 Jan; 39(1):86-90. PubMed ID: 30215235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs.
    Liu Y; Chen R; Liu W; Si L; Li L; Li X; Yao Z; Liao H; Wang J; Li Y; Zhao J; Xu D
    Antiviral Res; 2021 May; 189():105058. PubMed ID: 33711338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.
    Tan YW; Ye Y; Ge GH; Zhao W; Gan JH; Zhao Y; Niu ZL; Zhang DJ; Chen L; Yu XJ; Yang LJ
    World J Gastroenterol; 2015 Feb; 21(7):2089-95. PubMed ID: 25717242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the Abbott RealTime HBV DNA assay and comparison to the Cobas AmpliPrep/Cobas TaqMan 48 assay in monitoring patients with chronic cases of hepatitis B.
    Ciotti M; Marcuccilli F; Guenci T; Prignano MG; Perno CF
    J Clin Microbiol; 2008 Apr; 46(4):1517-9. PubMed ID: 18272717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response-guided treatment of cirrhotic chronic hepatitis B patients: multicenter prospective study.
    Gu EL; Yu YQ; Wang JL; Ji YY; Ma XY; Xie Q; Pan HY; Wu SM; Li J; Chen CW; Xu XW; Wang YE; Yao GB; Wang H; Zhang WH
    World J Gastroenterol; 2015 Jan; 21(2):653-60. PubMed ID: 25605989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of tenofovir disoproxil fumarate resistance after complete viral suppression in a patient with treatment-naïve chronic hepatitis B: A case report and review of the literature.
    Cho WH; Lee HJ; Bang KB; Kim SB; Song IH
    World J Gastroenterol; 2018 May; 24(17):1919-1924. PubMed ID: 29740207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Relationship between hepatitis B virus YMDD mutation and serum viral DNA loadings].
    Kong LH; Gao SX; Gui YP; Liu WH
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1262-3. PubMed ID: 17715043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
    Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
    J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants.
    Li P; Geng J; Li W; Xu X; Zhang X; Zheng W; Yu Y; Yang Z; Wang M
    Virol J; 2017 Apr; 14(1):68. PubMed ID: 28376852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly sensitive and specific detection of hepatitis B virus DNA and drug resistance mutations utilizing the PCR-based CRISPR-Cas13a system.
    Wang S; Li H; Kou Z; Ren F; Jin Y; Yang L; Dong X; Yang M; Zhao J; Liu H; Dong N; Jia L; Chen X; Zhou Y; Qiu S; Hao R; Song H
    Clin Microbiol Infect; 2021 Mar; 27(3):443-450. PubMed ID: 32360447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [HBV pol/S gene mutations in chronic hepatitis B patients receiving nucleoside/nucleotide analogues treatment].
    Kırdar S; Yaşa MH; Sayan M; Aydın N
    Mikrobiyol Bul; 2019 Apr; 53(2):144-155. PubMed ID: 31130119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.